Hospital Universitary de Bellvitge is identified in the evidence as a nephrology center in L’Hospitalet de Llobregat, Barcelona, associated with the University of Barcelona and IDIBELL. Its clinical and academic role is especially visible in work on hepatitis C virus infection among patients receiving dialysis or kidney transplantation, where diagnosis, liver assessment, infection prevention, antiviral treatment, and renal-allograft complications must be managed as one connected clinical problem.

Setting and Institutional Identity

Hospital Universitary de Bellvitge is located in L’Hospitalet de Llobregat, Barcelona, and its Nephrology Department is affiliated with the University of Barcelona and IDIBELL. The evidence presents the institution through specialist authorship rather than through a general institutional history: its named contribution is to nephrology research and clinical interpretation of hepatitis C in patients with advanced kidney disease and renal allografts.

That setting places the hospital at the intersection of several systems of care. Patients with chronic kidney disease may undergo long-term hemodialysis, enter a kidney-transplant waiting list, receive antiviral therapy, or proceed to transplantation while carrying risks related to liver disease and immunosuppression. The hospital’s documented work therefore treats hepatitis C not as an isolated liver diagnosis but as a condition that changes renal management, transplantation eligibility, infection-control priorities, and long-term graft outcomes.

Diagnostic and Clinical Framework

The clinical framework represented in the evidence distinguishes exposure or previous infection from active chronic infection. Anti-HCV antibodies are detected with third-generation enzyme-linked immunosorbent assays, while active infection is established by detecting HCV RNA in serum with sensitive molecular testing; the threshold is approximately 15 IU/ml. Chronic infection requires both anti-HCV positivity and HCV RNA positivity persisting for more than six months. This distinction prevents antibody status alone from being treated as proof of ongoing viral replication.

Once active chronic infection is established, assessment must cover both hepatic and extrahepatic effects. Liver injury can be evaluated by biopsy or by noninvasive methods, including biochemical scores and FibroScan-based elastometry, which measures liver stiffness and can reduce the need for approximately half of liver biopsies in some settings. The extrahepatic assessment is equally important because hepatitis C may produce cryoglobulinemia-associated vasculitis and renal disease even when liver-enzyme abnormalities are slight.

The associated renal syndrome is clinically varied. Hepatitis C is the major cause of mixed cryoglobulinemia, a systemic vasculitis that may involve arthralgias, arthritis, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and kidney disease. Renal manifestations include proteinuria, hematuria, and reduced estimated glomerular filtration rate; acute nephritic syndrome or nephrotic syndrome may be the presenting pattern. Type II mixed cryoglobulinemia and type I membranoproliferative glomerulonephritis, also called cryoglobulinemic glomerulonephritis, are especially associated with the infection.

Dialysis Care and Infection Control

In patients receiving long-term dialysis, hepatitis C-related liver disease is often asymptomatic. Fatigue, asthenia, and cognitive impairment may be difficult to attribute because they are also common in the dialysis population without hepatitis C. Biochemical clues can include elevated transaminases and gamma-glutamyl transpeptidase, while large dialysis cohorts have also found an association between anti-HCV seropositivity and alkaline-phosphatase activity. Higher intact parathormone levels have been observed in infected patients, a finding linked to hepatic osteodystrophy, although competing comorbidities can lead clinicians to overlook such abnormalities. Cirrhosis remains relatively infrequent among dialysis patients in the Western world, reported in some international registries in approximately 1.5–2% of cases.

The evidence also situates Hospital Universitary de Bellvitge’s subject within the problem of transmission inside hemodialysis units. Molecular studies have demonstrated clusters of closely related HCV isolates among patients treated in the same units, but a KDIGO review of 20 studies found that none conclusively established a specific transmission route. All nevertheless pointed to failures in infection-control procedures as the probable cause of new cases. In 18 of the 20 studies, some or all newly infected patients had not shared a dialysis machine with the source patient, making the internal machine circuit, if involved at all, a minor contributor.

Accordingly, dedicated machines for HCV-infected patients are not recommended, and patient isolation is not considered an adequate substitute for strict infection-control practice. The preventive emphasis falls on staff behavior and station hygiene: handwashing before and after patient or equipment contact, alcohol-based hand rub when hands are not visibly contaminated, disposable gloves, removal of gloves when leaving the station, disposal of single-use items, disinfection or patient dedication of reusable equipment, and cleaning of potentially contaminated surfaces after every session. The guidelines also call for appropriate waste management and regular observational audits, because agreement on precautions does not ensure that they are consistently applied.

Treatment, Transplantation, and Institutional Consequences

Antiviral treatment is recommended at any stage of hepatitis C infection, with duration shaped by genotype and viral kinetics. In acute infection, persistent HCV RNA after an average of 12 weeks supports a 24-week course of pegylated interferon; treatment may extend to 48 weeks when RNA remains detectable at week 4 or week 12. In chronic infection, treatment may be considered for any patient under contemporary European guidance, with particular emphasis on significant fatigue, necroinflammatory hepatitis, fibrosis above stage 1 on the Metavir scale, or symptomatic extrahepatic disease such as cryoglobulinemia-associated vasculitis with renal involvement.

Treatment is difficult in end-stage renal disease because toxicity affects both adherence and quality of life. Interferon-based therapy may cause flu-like symptoms, fever, fatigue, headache, myalgia, and arthralgia, as well as anemia, neutropenia, depression, and anxiety. Dose reduction occurs in roughly 35–42% of treated patients, and treatment is discontinued in about 30%. These harms are clinically consequential in a population already burdened by dialysis-related symptoms and depression. Infected dialysis patients may also have reduced mental quality-of-life scores: in one study of 165 patients, anti-HCV positivity was independently associated with a lower mental component summary score, although no association with the physical component score was found.

The transplant pathway adds another layer of surveillance. Chronic HCV infection before transplantation has been reported in 7–40% of kidney recipients, with risk related to longer duration of end-stage renal disease, prior transplantation, black race, hepatitis B coinfection, substance-abuse history, and diabetes mellitus. Up to one quarter of candidates with active infection have advanced liver fibrosis despite otherwise well-compensated disease. Candidates therefore require serologic and molecular screening, and the KDIGO workgroup recommended percutaneous liver biopsy for all HCV-infected patients being considered for kidney transplantation because noninvasive tests had not yet matched biopsy accuracy.

Waiting-list management converts virologic status into an ongoing institutional decision. Patients with positive NAT results may be placed on hold and referred to a hepatologist for evaluation and possible treatment. Those who achieve sustained virologic response require at least annual NAT testing to confirm durability; relapse prompts renewed hold status and consideration of retreatment. Candidates who remain viremic require annual assessment for liver-disease progression. Long waiting periods make this surveillance especially important, since some areas of the United States have approached five to seven years for a deceased-donor kidney. In one series, 8 of 13 candidates who underwent repeat biopsy while waiting showed worsening liver histology, compared with 7 of 31 follow-up biopsies obtained after transplantation.

Post-Transplant Renal Disease and Research Significance

The post-transplant evidence associated with the hospital shows why viral clearance and renal surveillance are inseparable. HCV infection is a major independent risk factor for renal-allograft loss and has been linked to glomerulitis and transplant glomerulopathy, lesions associated with anti-HLA antibodies and antibody-mediated rejection. HCV-infected recipients may also develop thrombotic microangiopathy in the presence of pretransplant anticardiolipin antibodies, although this complication is uncommon.

HCV-infected renal and liver allograft recipients are vulnerable to immune-complex-mediated glomerulonephritis. De novo membranoproliferative glomerulonephritis has been reported in HCV-infected renal allograft recipients, later linked to type II mixed cryoglobulinemia with an IgM-kappa monoclonal component. Cryocrit levels are often below 5% after transplantation, which can make cryoglobulin detection and characterization difficult, while HCV RNA may be substantially higher in the cryocrit than in serum, supporting a pathogenic role for the virus and possible activation of the classical complement pathway.

The clinical presentation of post-transplant membranoproliferative glomerulonephritis includes hypertension, microhematuria, proteinuria, renal dysfunction, and sometimes nephrotic syndrome. Biopsy may show mesangial proliferation, double contours, and parietal IgM and C3 deposits. Electron microscopy helps distinguish membranoproliferative glomerulonephritis from transplant glomerulopathy: the former has subendothelial electron-dense deposits, whereas transplant glomerulopathy shows radiolucent areas in the glomerular basement membrane. The two lesions can coexist, making humoral immunity and autoimmunity complementary sources of graft injury rather than mutually exclusive explanations.

The hospital’s documented nephrology work therefore carries significance beyond a single diagnosis or procedure. It joins molecular confirmation of infection to the lived burden of fatigue, depression, and treatment toxicity; it joins dialysis-station hygiene to the governance of transmission risk; and it joins liver biopsy and waiting-list review to the protection of a future renal graft. In this evidence, Hospital Universitary de Bellvitge functions as a clinical and research site where hepatitis C is made legible across laboratory, renal, hepatic, immunological, and institutional domains.